Observational study on long-term treatment of schizophrenia with atypical antipsychotics

An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia

This study is testing how well long-term treatment with certain antipsychotic medications works for people with schizophrenia in China.

Quick facts

• Study type: Observational
• Enrollment: 3000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Shanghai Mental Health Center (Academic / other)
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT02640911 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the safety and efficacy of long-term treatment with atypical antipsychotics in patients diagnosed with schizophrenia in China. The study will involve a cohort of 3000 patients and will assess various factors including symptoms, social functioning, recurrence rates, and hospitalization. Participants will undergo multiple assessments over a period of 156 weeks, including physical examinations, laboratory tests, and monitoring of adverse events. The study focuses on medications such as quetiapine, olanzapine, and clozapine, among others.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who have a diagnosis of schizophrenia and are currently taking or will take atypical antipsychotics.

Not a fit: Patients who are participating in other clinical studies or have conditions that make them unsuitable for this study may not benefit.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of atypical antipsychotics for patients with schizophrenia.

How similar studies have performed: Other studies have shown varying degrees of success in evaluating the safety and efficacy of atypical antipsychotics, making this study a continuation of existing research rather than a completely novel approach.

Eligibility criteria

Inclusion Criteria:

1. An in-patient or out-patient (male or female) and aged ≥18 years
2. A diagnosis of schizophrenia,DSM-IV(Diagnostic and Statistical Manual Diploma in Social Medicine-IV)
3. Subjects must have the ability to effectively communicate with investigator,complete study related documents, comprehend the key components of the consent form and must provide written informed consent to participate in the study prior to any study specific assessments or procedures.
4. Patients are taking or will take atypical antipsychotics which include quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, paliperidone , amisulpride , perospirone and clozapine

Exclusion Criteria:

1. Participation in other clinical studies.
2. Other conditions which, in the investigator's judgment, render patients unsuitable for the clinical study.

Where this trial is running

Shanghai, Shanghai Municipality

• Shanghai Mental Health Center — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Study coordinator: Huafang Li, PH.D

Conditions Schizophrenia